Enhertu, an oncology drug marketed by UK giant AstraZeneca, topped the list of highest-selling new drugs in 2024. A cancer drug topping the sales charts also highlights the growing incidence of the disease in the country. In total, over 3,100 new brands were introduced during the year, collectively registering sales of Rs 1,097 crore, the latest data culled from IQVIA showed. GSK’s Augmentin continued to be number 1 brand with revenues of Rs 830 crore, growing by 9.3% for the 12-month period. Overall, the domestic pharma market stands at over Rs 2.2 lakh crore, with growth of a little over 8%. In Jan, the growth was led by price increases contributing over 5%, and new product introduction 2.6%, while volume growth was 0.9%. The market is growing at a steady rate between 8-10% with certain players, including Sun Pharma and Torrent, exhibiting healthy double-digit growth.
Enhertu, an oncology drug marketed by UK giant AstraZeneca, ….
